Thomas Janet L, Guo Hongfei, Lynam Ian M, Powell Joshua N, Okuyemi Kolawole S, Bronars Carrie A, Ahluwalia Jasjit S
Department of Medicine, Division of General Internal Medicine, Program in Health Disparities Research, University of Minnesota, Minneapolis, MN 55414, USA.
J Gen Intern Med. 2008 Sep;23(9):1361-6. doi: 10.1007/s11606-008-0656-3. Epub 2008 Jun 29.
The double-blind placebo-controlled design is commonly considered the gold standard in research methodology; however, subject expectation bias could subvert blinding.
The primary aim of this study was to examine the impact of expectation bias. Specifically, we examined perceived treatment assignment on smoking cessation outcome rates among participants enrolled in a clinical trial of bupropion (150 mg SR, BID).
Analyses were conducted on data collected during "Kick It at Swope," a double-blind, placebo-controlled, randomized trial of 600 African-American smokers. Chi-square and multiple logistic regression analyses were used to examine the impact of perception of assignment on treatment effect and cotinine-verified smoking abstinence rates.
Participants were predominantly middle-aged (mean 44.7, SD 11.2), African-American women (68.6%), who smoked 19 CPD (SD = 8.1). Most had completed at least a high school education or GED (51.6%), and 55% had a monthly family income <$1,800.
At week 6 (end of treatment) and week 26 (end of study), participants were asked to report their perceived treatment group assignment. Self-reported abstinence (weeks 6 and 26) was confirmed using CO and cotinine biochemical verification.
After adjusting for actual treatment assignment, age and baseline cotinine, participants who perceived being assigned to bupropion vs. placebo were more likely to be abstinent at weeks 6 (OR = 2.07, 95% CI: 1.29 to 3.33, p = 0.002) and 26 (OR = 1.85, 95% CI: 1.05 to 3.24, p = 0.032).
Results support previous research that expectation bias associated with judgment of treatment assignment is a strong predictor of outcome and confirms this relationship in a smoking cessation trial using bupropion SR among African-American smokers.
双盲安慰剂对照设计通常被认为是研究方法中的金标准;然而,受试者期望偏差可能会破坏盲法。
本研究的主要目的是检验期望偏差的影响。具体而言,我们研究了在参与安非他酮(150毫克缓释片,每日两次)临床试验的参与者中,对治疗分配的认知对戒烟成功率的影响。
对在“在斯沃普戒烟”期间收集的数据进行分析,这是一项针对600名非裔美国吸烟者的双盲、安慰剂对照随机试验。采用卡方检验和多元逻辑回归分析来研究对分配的认知对治疗效果和经可替宁验证的戒烟率的影响。
参与者主要为中年(平均44.7岁,标准差11.2)非裔美国女性(68.6%),每天吸烟19支(标准差 = 8.1)。大多数人至少完成了高中教育或获得了同等学历证书(51.6%),55%的人家庭月收入低于1800美元。
在第6周(治疗结束时)和第26周(研究结束时),要求参与者报告他们认为的治疗组分配情况。自我报告的戒烟情况(第6周和第26周)通过一氧化碳和可替宁生化验证来确认。
在调整了实际治疗分配、年龄和基线可替宁后,认为被分配到安非他酮组而非安慰剂组的参与者在第6周(优势比 = 2.07,95%置信区间:1.29至3.33,p = 0.002)和第26周(优势比 = 1.85,95%置信区间:1.05至3.24,p = 0.032)更有可能戒烟。
结果支持了先前的研究,即与治疗分配判断相关的期望偏差是结果的有力预测因素,并在一项针对非裔美国吸烟者使用安非他酮缓释片的戒烟试验中证实了这种关系。